With the well-known fact that blood glucose levels (BGL) fluctuate moment-to-moment, and certainly day-by-day, it might be a bit surprising to hear that a diabetes medication could be developed that only needs once-weekly administration. But it's true -- Amylin and Eli Lilly have developed a once-weekly formulation of Byetta (exenatide), their GLP-1 analog drug for type 2 diabetes that presently requires injection twice-daily. The long-acting version of Byetta, nicknamed Byetta LAR (Byetta Longer-Acting Release), has completed phase III trials, and is presently undergoing review by the FDA; it is anticipated that it could be on the US market as soon as mid-year 2010. [Editor's Note: The once-weekly version of Byetta, called Bydureon, was approved by the FDA in January, 2012.]
Some study results about Byetta LAR are published: examples include:
Byetta LAR is not the only once-weekly diabetes drug in development: Roche is developing another drug, taspoglutide, which is in the same class as Byetta, and also would be injected once-weekly. This past week,
Roche announced the results of a
phase III trial (T-emerge 2 (subcutaneous weekly taspoglutide versus subcutaneous twice-daily exenatide, as add-on to metformin, a thiazolidinedione,
or metformin and a thiazolidinedione), with 1189 T2DM
patients): after 24 weeks of treatment, patients receiving the Roche drug had a greater decline in their BGL than those who had been given Byetta; the most frequently reported side effects from both drugs were nausea and vomiting. Results from other phase III studies on the new Roche drug are expected to become available soon, allowing Roche to proceed to filing for approval to sell their drug in the second half of 2010; if they do, they might have their product on the US market in 2011.
Novo-Nordisk has a third GLP-1 analog drug: Victoza (liraglutide), which is designed to be administered by injection once-daily. This drug has been reviewed by an FDA Advisory Committee, and safety concerns have held up FDA approval, although it's already been approved in Europe. Novo-Nordisk is also said to be running once-weekly trials with liraglutide, but I haven't found any published results, and they don't mention it in their pipeline at their corporate website. They do mention another name, semaglutide, which they describe as "a longer-acting human GLP-1 analogue intended for once-weekly administration." At ClinicalTrials.gov, there are several studies listed for NN9535, which is being evaluated for once-weekly administration, and which is described as a GLP-1 analog and according to other reports is semaglutide -- possibly semaglutide is their once-weekly formulation of liraglutide (or perhaps it's another molecule).
In addition to these three GLP-1 analogs, are there any other drugs being evaluated for once-weekly therapy of diabetes?
Once weekly dosing with long-lasting basal insulins such as Lantus (insulin glargine) might be possible. One mention of this concept is described by Complex Biosystems: "Once-weekly basal insulin is being developed at Complex on the hypothesis that a significant patient population within Type II diabetics would embrace such a medication ... Depot insulin, administered once a week in Type II, would catalyze earlier entry into insulin therapy and provide better overall glucose level control."
And other diabetes drugs, by the nature of how they work, might be amenable to once-weekly dosing. I thought I might be able to Google some information about trying metformin on a once-weekly basis, but I struck out.
Many other drugs for other medical conditions work on a once-weekly basis, and as one study mentioned above indicated, apparently patients prefer weekly dosing to daily or several times daily. Assuming Byetta LAR is approved by the FDA, and later, Roche's once-weekly drug, I suspect there will be a considerable push by drug manufacturers (and their marketing departments) to develop weekly versions of other diabetes drugs.